Dr. Glaucomflecken Explains: Intensive LDL Cholesterol Targeting in Atherosclerotic CVD (Ez-PAVE) @NEJMgroup
Dr. Glaucomflecken Explains: Intensive LDL Cholesterol Targeting in Atherosclerotic CVD (Ez-PAVE) @NEJMgroup
Uploaded May 2026 | Updated September 2026, 1 week ago
This video in our partnership with @DGlaucomflecken explains a randomized trial evaluating the appropriate low-density lipoprotein (LDL) cholesterol target for secondary prevention in patients with atherosclerotic cardiovascular disease.

View the Original Article for free: https://nej.md/DrG41

#cardiology #medicaleducation #nejm
Dr. Glaucomflecken Explains: Intensive LDL Cholesterol Targeting in Atherosclerotic CVD (Ez-PAVE)Clinical Problem-Solving: Too Much of a Good ThingNEJM Clinician: Are PPIs Linked to COPD Flares?Naomi T. Nkinsi, MD, MPH, on Racial Bias in Diagnosing Kidney DiseaseAaron Baugh, MD, on Race-Specific Equations for Lung FunctionNEJM Interview: Lawrence Casalino on qualities of corporate organizations that could affect physi...GLP-1s and Pancreatitis: New DataImprovements in Hearing and Speech Perception after Gene Therapy and Contralateral Cochlear ImplantImage Challenge โ€” March 26, 2026Perspective Video Interview: Using AI-Based Clinical Tools at the BedsideThree Studies That Made Headlines in AprilBeyond Journal Club: Dr. Elliot Tapper on Managing MASLD
NEJM Group |

Dr. Glaucomflecken Explains: Intensive LDL Cholesterol Targeting in Atherosclerotic CVD (Ez-PAVE)

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER